Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Pharmacology and Therapeutics"
DOI: 10.5414/cp203418
Abstract: Objective: Bococizumab, a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, has been shown to reduce low-density lipoprotein cholesterol (LDL-C). Here, we describe the pharmacokinetics and pharmacodynamics of bococizumab and its effect on lipoprotein particle… read more here.
Keywords: pharmacokinetics exploratory; efficacy biomarkers; monoclonal antibody; exploratory efficacy ... See more keywords